Investigational ADC Shows Promise in Advanced Endometrial Cancer

By News Health
6 hours Ago

(MedPage Today) — Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed promising efficacy in patients with advanced or metastatic endometrial cancer, according to results from…

Source link : https://www.medpagetoday.com/meetingcoverage/sgo/114718

Author :

Publish date : 2025-03-18 20:06:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Flurry of worry over benefit changes

Better Response, Survival in Head and Neck Cancer With Dual Pre-Op Immunotherapy

Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy

Texas Midwife Accused by State's Attorney General of Providing Illegal Abortions

Transplant Doc's Future in U.S. Uncertain Following Her Deportation to Lebanon

This Vaccine Researcher Was Caught in the NIH Funding Cut Crossfire